Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $469.50 Consensus Target Price from Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have received an average recommendation of “Hold” from the fifteen research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $469.50.

MEDP has been the topic of a number of research reports. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and boosted their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Royal Bank Of Canada decreased their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Barclays cut their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Finally, BMO Capital Markets reduced their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MEDP. BOKF NA lifted its position in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after purchasing an additional 20 shares during the last quarter. Valeo Financial Advisors LLC grew its stake in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after buying an additional 21 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after buying an additional 24 shares during the last quarter. Schulhoff & Co. Inc. increased its holdings in shares of Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after buying an additional 25 shares during the last quarter. Finally, Kaufman Rossin Wealth LLC raised its position in shares of Medpace by 3.4% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock valued at $447,000 after buying an additional 26 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Down 1.8%

Shares of MEDP stock opened at $527.93 on Thursday. Medpace has a 12-month low of $306.70 and a 12-month high of $628.92. The firm has a fifty day moving average of $480.31 and a 200-day moving average of $493.94. The company has a market capitalization of $15.08 billion, a price-to-earnings ratio of 33.18, a P/E/G ratio of 2.69 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm’s revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts expect that Medpace will post 17.04 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.